AR118144A1 - Anticuerpos anti-trem2 y métodos para utilizarlos - Google Patents
Anticuerpos anti-trem2 y métodos para utilizarlosInfo
- Publication number
- AR118144A1 AR118144A1 ARP200100461A ARP200100461A AR118144A1 AR 118144 A1 AR118144 A1 AR 118144A1 AR P200100461 A ARP200100461 A AR P200100461A AR P200100461 A ARP200100461 A AR P200100461A AR 118144 A1 AR118144 A1 AR 118144A1
- Authority
- AR
- Argentina
- Prior art keywords
- trem2
- methods
- trem2 antibodies
- antibodies
- antibody
- Prior art date
Links
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 3
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118144A1 true AR118144A1 (es) | 2021-09-22 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100461A AR118144A1 (es) | 2019-02-20 | 2020-02-20 | Anticuerpos anti-trem2 y métodos para utilizarlos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220073609A1 (enExample) |
| EP (1) | EP3927743A1 (enExample) |
| JP (2) | JP7543290B2 (enExample) |
| KR (1) | KR20210135518A (enExample) |
| CN (1) | CN113614110B (enExample) |
| AR (1) | AR118144A1 (enExample) |
| AU (1) | AU2020226754A1 (enExample) |
| BR (1) | BR112021015656A2 (enExample) |
| CA (1) | CA3130086A1 (enExample) |
| CL (1) | CL2021002206A1 (enExample) |
| CO (1) | CO2021012230A2 (enExample) |
| EA (1) | EA202192294A1 (enExample) |
| EC (1) | ECSP21069105A (enExample) |
| IL (1) | IL285651A (enExample) |
| MA (1) | MA55025A (enExample) |
| MX (1) | MX2021009722A (enExample) |
| PE (1) | PE20211979A1 (enExample) |
| PH (1) | PH12021552002A1 (enExample) |
| SG (1) | SG11202108734VA (enExample) |
| TW (1) | TWI879756B (enExample) |
| WO (2) | WO2020172457A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3902836A4 (en) * | 2018-12-18 | 2022-08-31 | Boehringer Ingelheim IO Canada Inc. | FLT3 AGONISTIC ANTIBODIES AND THEIR USES |
| PE20211979A1 (es) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4337317A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
| CN118765204A (zh) | 2022-02-23 | 2024-10-11 | 艾利妥 | 抗trem2抗体的使用方法 |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2024160736A1 (en) | 2023-01-30 | 2024-08-08 | Isar Bioscience Gmbh | Human anti-trem2 antibody for treating neurodegenerative disorders |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| US20250101101A1 (en) | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025106361A1 (en) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Human nectin-4 binders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| CA2746470A1 (en) | 2009-01-06 | 2010-07-15 | Raymond-David Pridmore | Processing of macronutrients |
| EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| EP3041865A2 (en) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| KR102506663B1 (ko) | 2014-09-28 | 2023-03-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| EP3277305B1 (en) | 2015-03-31 | 2021-07-21 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| WO2017062672A2 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| EP3559043A4 (en) | 2016-12-23 | 2020-08-05 | Bluefin Biomedicine, Inc. | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
| US20190367623A1 (en) | 2017-01-17 | 2019-12-05 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| PL3583120T3 (pl) | 2017-02-17 | 2023-01-09 | Denali Therapeutics Inc. | Konstruowane polipeptydy wiążące receptory transferyny |
| MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| AU2018307877A1 (en) | 2017-07-27 | 2020-01-02 | Novartis Ag | Sheddase resistant TREM2 variants |
| CA3061755A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| PT3665192T (pt) | 2017-08-10 | 2023-09-25 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
| CA3075285A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| AU2019207735A1 (en) | 2018-01-10 | 2020-07-23 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| US20210284702A1 (en) | 2018-06-18 | 2021-09-16 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| CN112839955A (zh) | 2018-08-16 | 2021-05-25 | 戴纳立制药公司 | 经工程改造双特异性蛋白 |
| SG11202101436SA (en) | 2018-08-22 | 2021-03-30 | Denali Therapeutics Inc | Anti-her2 polypeptides and methods of use thereof |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| WO2020112889A2 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| CA3121927A1 (en) | 2018-12-10 | 2020-06-18 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| CA3122725A1 (en) | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| KR20210104079A (ko) | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| PE20211979A1 (es) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| BR112021019520A2 (pt) | 2019-04-03 | 2021-12-07 | Denali Therapeutics Inc | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica |
| CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| AR121384A1 (es) | 2020-02-19 | 2022-06-01 | Denali Therapeutics Inc | Proteínas biespecíficas anti-her2 diseñadas por ingeniería genética |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
-
2020
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko active Pending
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
-
2021
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP2024164116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113614110B (zh) | 2025-03-25 |
| TWI879756B (zh) | 2025-04-11 |
| JP7543290B2 (ja) | 2024-09-02 |
| CN113614110A (zh) | 2021-11-05 |
| EP3927743A1 (en) | 2021-12-29 |
| ECSP21069105A (es) | 2021-11-18 |
| JP2022520868A (ja) | 2022-04-01 |
| PH12021552002A1 (en) | 2022-09-19 |
| US12240902B2 (en) | 2025-03-04 |
| WO2020172457A1 (en) | 2020-08-27 |
| JP2024164116A (ja) | 2024-11-26 |
| EA202192294A1 (ru) | 2021-12-24 |
| TW202045543A (zh) | 2020-12-16 |
| PE20211979A1 (es) | 2021-10-05 |
| US20220073609A1 (en) | 2022-03-10 |
| SG11202108734VA (en) | 2021-09-29 |
| US20220119522A1 (en) | 2022-04-21 |
| MA55025A (fr) | 2021-12-29 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| MX2021009722A (es) | 2021-09-14 |
| KR20210135518A (ko) | 2021-11-15 |
| WO2020172450A1 (en) | 2020-08-27 |
| IL285651A (en) | 2021-09-30 |
| CO2021012230A2 (es) | 2021-09-30 |
| AU2020226754A1 (en) | 2021-09-16 |
| CA3130086A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021012230A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CO2022009744A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| CL2022001886A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| CO2021006911A2 (es) | Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| MX2024005009A (es) | Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
| CO2021016907A2 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| CL2021003563A1 (es) | Anticuerpos para la unión a psma | |
| AR069775A1 (es) | Anticuerpos bivalentes biespecificos | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| CO2019009035A2 (es) | Proteínas de unión al receptor de glucagón y métodos para usarlas | |
| CL2022001541A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso. | |
| MX2025005542A (es) | Moléculas antagonistas de fcrn y métodos de uso de estas | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| CL2025002112A1 (es) | Anticuerpo anti-npr1; método de producción; y su uso. | |
| CL2022000752A1 (es) | Molécula de unión específica para lif y uso de la misma | |
| AR110908A1 (es) | Constructo promotor para la síntesis de proteínas libre de células | |
| MX2021012848A (es) | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. | |
| MX2020008114A (es) | Cuantificacion y modelado de atributos de calidad de anticuerpos monoclonales terapeuticos. | |
| AR122678A1 (es) | Agentes de unión a lair-1 y métodos para su uso |